Current treatment strategies for advanced prostate cancer
During the past decade, treatment strategies for patients with advanced prostate cancer
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …
[HTML][HTML] Cross-resistance and drug sequence in prostate cancer
The treatment landscape of advanced prostate cancer has widely expanded over the past
years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving …
years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving …
Olaparib for metastatic castration-resistant prostate cancer
Background Multiple loss-of-function alterations in genes that are involved in DNA repair,
including homologous recombination repair, are associated with response to poly …
including homologous recombination repair, are associated with response to poly …
[HTML][HTML] Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer
Background The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–
targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration …
targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration …
TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic …
PURPOSE Prostate cancer (PCa) becomes resistant to androgen ablation through adaptive
upregulation of the androgen receptor in response to the low-testosterone …
upregulation of the androgen receptor in response to the low-testosterone …
Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer—where are we now?
Simple Summary The past decade has seen the development and regulatory approval of a
large number of new treatment options for advanced prostate cancer. Despite this, the two …
large number of new treatment options for advanced prostate cancer. Despite this, the two …
[HTML][HTML] Abiraterone acetate in the treatment of prostate cancer
Among all cancer-related death, prostate cancer accounts for the second prominent reason
for cancer-associated death in men. Despite the castration mediated reduction in …
for cancer-associated death in men. Despite the castration mediated reduction in …
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
T Sumiyoshi, K Mizuno, T Yamasaki, Y Miyazaki… - Scientific Reports, 2019 - nature.com
The therapeutic landscape of castration-resistant prostate cancer (CRPC) has rapidly
expanded. There is a need to develop noninvasive biomarkers to guide treatment. We …
expanded. There is a need to develop noninvasive biomarkers to guide treatment. We …
Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
Y Ito, MD Sadar - Research and Reports in Urology, 2018 - Taylor & Francis
Enzalutamide is a nonsteroidal antiandrogen for the treatment of metastatic castration-
resistant prostate cancer (mCRPC) both before and after chemotherapy. Enzalutamide is …
resistant prostate cancer (mCRPC) both before and after chemotherapy. Enzalutamide is …
Recommandations françaises du Comité de cancérologie de l'AFU–actualisation 2020–2022: cancer de la prostate
F Rozet, P Mongiat-Artus, C Hennequin, JB Beauval… - Progrès en Urologie, 2020 - Elsevier
Objective.-The purpose of the guidelines national committee ccAFU was to propose updated
french guidelines for prostate cancer. Methods.-A Medline search was achieved between …
french guidelines for prostate cancer. Methods.-A Medline search was achieved between …